# Study to Evaluate the Safety of a Gene and Cell Therapy Product in Participants With HIV That is Well-Controlled on Antiretroviral Therapy

> **NCT04561258** · PHASE1 · COMPLETED · sponsor: **American Gene Technologies International Inc.** · enrollment: 7 (actual)

## Conditions studied

- HIV

## Interventions

- **BIOLOGICAL:** AGT103-T

## Key facts

- **NCT ID:** NCT04561258
- **Lead sponsor:** American Gene Technologies International Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-12
- **Primary completion:** 2022-08-15
- **Final completion:** 2022-11-21
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04561258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04561258, "Study to Evaluate the Safety of a Gene and Cell Therapy Product in Participants With HIV That is Well-Controlled on Antiretroviral Therapy". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04561258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*